411 Swedeland Road
King of Prussia
26 articles about Wuxi Biologics
WuXi Biologics Successfully Implemented a Fully Integrated Continuous Process with a Breakthrough Productivity of ~6 g/L/day at Pilot Scale
WuXi Biologics announced that it has accomplished end-to-end DS manufacturing at pilot scale utilizing WuXiUPTM, a proprietary ultra-high productivity continuous bioprocessing platform at its non-GMP pilot plant in Shanghai, China.
Myricx Bio and WuXi Biologics announce that they have entered into a license agreement under which Myricx will have exclusive access to a proprietary antibody that was discovered based on WuXi Bio’s integrated technology platforms.
WuXi Biologics Launches New High-Productivity Bioprocessing Platform WuXiUI™ for Cost-Effective Commercial Manufacturing and Desirable Product Quality
WuXi Biologics announced that it has launched a new proprietary bioprocessing platform WuXiUI™, an ultra-intensified, fed-batch solution that enhances the productivity and quality of multiple different CHO or other mammalian cell lines and product modalities.
IMIDomics Announces Strategic Agreement with WuXi Biologics to Advance IMB1001 Antibody Development for Immune-Mediated Inflammatory Diseases
IMIDomics Inc. today announced that it has entered into an agreement with WuXi Biologics, a global Contract Research, Development and Manufacturing Organization, aimed at accelerating the development and manufacturing of IMIDomics IMB1001.
PharmaEssentia Enters Into Exclusive Global License Agreement With WuXi Biologics for a Myeloid Immune Checkpoint Antibody Candidate
PharmaEssentia Corporation , today announced it has entered into a license agreement with WuXi Biologics Ireland Limited to obtain the global exclusive rights to research, develop, manufacture and commercialize a myeloid immune checkpoint antibody candidate.
WuXi Biologics Congratulates Amicus Therapeutics on U.S. FDA Approval for New Treatment for Pompe Disease
WuXi Biologics, a leading global Contract Research, Development and Manufacturing Organization, congratulates its strategic partner, Amicus Therapeutics, on receiving U.S. FDA's approval for Pombiliti™ + Opfolda™ 65mg capsules.
Mabwell and WuXi XDC Sign Long-Term ADC Strategic Collaboration to Accelerate Global Layout of Innovative Biologics
Mabwell, an innovative biopharmaceutical company with entire industry chain, and WuXi XDC, a leading global CRDMO, joint announced that they have signed a LOI for long-term strategic collaboration on Mabwell's multiple ADC projects.
Pharmadule Morimatsu and WuXi Biologics officially entered into a global strategic cooperation for the Singapore CRDMO Center project of WuXi Biologics.
WuXi Biologics, a leading global Contract Research, Development, and Manufacturing Organization, announced that the International Society for Pharmaceutical Engineering has awarded the company a 2023 Facility of the Year Award in the Operations category.
WuXi Biologics Congratulates Amicus Therapeutics on European Commission Approval for Pombiliti™ in Patients with Late-Onset Pompe Disease
WuXi Biologics ("WuXi Bio") (2269.HK) congratulates its strategic partner Amicus Therapeutics ("Amicus") (Nasdaq: FOLD) on receiving European Commission's approval for Pombiliti™ (cipaglucosidase alfa), a long-term enzyme replacement therapy (ERT) used in combination with miglustat for adults with late-onset Pompe disease (LOPD).
WuXi Biologics and GSK Enter into License Agreement on Multiple Novel Bi- & Multi-specific T Cell Engagers
WuXi Biologics announced a license agreement with GSK plc under which GSK will have exclusive licenses for up to four bi- & multi-specific TCE antibodies developed using WuXi Biologics' proprietary technology platforms.
WuXi Biologics, a leading global Contract Research, Development and Manufacturing Organization, announced that its subsidiary WuXi Biologics Co., Ltd. has been removed from the Unverified List by the U.S. Department of Commerce, effective Dec. 16, 2022.
WuXi Biologics, a leading global Contract Research, Development and Manufacturing Organization, launched its Integrated Biologics CRDMO Center located in the district of Fengxian in Shanghai.
WuXi Biologics ("WuXi Bio") (2269.HK) and Toregem BioPharma today announced that they have signed a Memorandum of Understanding (MOU) to form a strategic partnership in the development of TRG035, a monoclonal antibody targeting USAG-1 for the treatment of congenital adentia.
WuXi Biologics, a leading global Contract Research, Development and Manufacturing Organization, announced that its subsidiary WuXi Biologics Co., Ltd. located in Wuxi city was removed from the Unverified List by the U.S. Department of Commerce, effective October 7, 2022.
The U.S. FDA had a busy week with a range of drug approvals, advisory committee meetings and classification announcements.
WuXi Biologics announced that its two Drug Substance facilities and a Drug Product facility located in Wuxi city received regulatory approvals from the European Medicines Agency and the U.S. Food and Drug Administration.
WuXi Biologics, a global leading Contract Research, Development and Manufacturing Organization, announced a 10-year USD$1.4 billion investment plan to expand the company's research, development, and large-scale drug substance and drug product manufacturing capacity and capabilities in Singapore.
Unnamed sources “familiar with the matter” informed Bloomberg that CStone's leadership team is working with Goldman Sachs to determine if there are interested buyers.
Many healthcare, pharmaceutical and biotech companies continue to place their bets on China, bringing fresh rounds of investments to and forging new partnerships with local firms.